Input: Article: Men typically wore a toga, and women a stola. The woman's stola differed in looks from a toga, and was usually brightly coloured. The cloth and the dress distinguished one class of people from the other class. The tunic worn by plebeians, or common people, like shepherds and slaves, was made from coarse and dark material, whereas the tunic worn by patricians was of linen or white wool. A knight or magistrate would wear an augusticlavus, a tunic bearing small purple studs. Senators wore tunics with broad red stripes, called tunica laticlavia. Military tunics were shorter than the ones worn by civilians. Boys, up until the festival of Liberalia, wore the toga praetexta, which was a toga with a crimson or purple border. The toga virilis, (or toga pura) was worn by men over the age of 16 to signify their citizenship in Rome. The toga picta was worn by triumphant generals and had embroidery of their skill on the battlefield. The toga pulla was worn when in mourning.[citation needed]

Now answer this question: How did a womans garment typically vary from a mans in the Roman Republic?

Output: usually brightly coloured

Input: Article: The Han dynasty (Chinese: ; pinyin: Han chao) was the second imperial dynasty of China, preceded by the Qin dynasty (221207 BC) and succeeded by the Three Kingdoms period (220280 AD). Spanning over four centuries, the Han period is considered a golden age in Chinese history. To this day, China's majority ethnic group refers to itself as the "Han people" and the Chinese script is referred to as "Han characters". It was founded by the rebel leader Liu Bang, known posthumously as Emperor Gaozu of Han, and briefly interrupted by the Xin dynasty (923 AD) of the former regent Wang Mang. This interregnum separates the Han dynasty into two periods: the Western Han or Former Han (206 BC 9 AD) and the Eastern Han or Later Han (25220 AD).

Now answer this question: What dynasty came before the Han dynasty?

Output: Qin

Input: Article: Drug discovery and development is very expensive; of all compounds investigated for use in humans only a small fraction are eventually approved in most nations by government appointed medical institutions or boards, who have to approve new drugs before they can be marketed in those countries. In 2010 18 NMEs (New Molecular Entities) were approved and three biologics by the FDA, or 21 in total, which is down from 26 in 2009 and 24 in 2008. On the other hand, there were only 18 approvals in total in 2007 and 22 back in 2006. Since 2001, the Center for Drug Evaluation and Research has averaged 22.9 approvals a year. This approval comes only after heavy investment in pre-clinical development and clinical trials, as well as a commitment to ongoing safety monitoring. Drugs which fail part-way through this process often incur large costs, while generating no revenue in return. If the cost of these failed drugs is taken into account, the cost of developing a successful new drug (new chemical entity, or NCE), has been estimated at about 1.3 billion USD(not including marketing expenses). Professors Light and Lexchin reported in 2012, however, that the rate of approval for new drugs has been a relatively stable average rate of 15 to 25 for decades.

Now answer this question: What does NMEs stand for?

Output:
New Molecular Entities